TY - CHAP
T1 - Personalized clinical approaches to anxiety disorders
AU - Perna, Giampaolo
AU - Alciati, Alessandra
AU - Sangiorgio, Erika
AU - Caldirola, Daniela
AU - Nemeroff, Charles B.
N1 - Funding Information:
Conflicts of Interest Dr. Charles B.Nemeroff’s disclosures are as follows: Dr. Nemeroff has received funding from NIH and the Stanley Medical Research Institute; he has served as a consultant to Bracket (Clintara), Gerson Lehrman Group Healthcare and Biomedical Council, Fortress Biotech, Sunovion Pharmaceuticals, Janssen Research and Development, Magstim, Navitor Pharmaceuticals, Intra-Cellular Therapies, Takeda, Taisho Pharmaceutical and Xhale; he has served on the boards of directors for the American Foundation for Suicide Prevention, Gratitude America and the Anxiety Disorders Association of America; he is a stockholder in AbbVie, Antares, Bracket Intermediate Holding Corp., Celgene, OPKO Health, Seattle Genetics and Xhale; he serves on the scientific advisory boards of the American Foundation for Suicide Prevention, the Anxiety Disorders Association of America, the Brain and Behavior Research Foundation, Bracket (Clintara), the Laureate Institute for Brain Research, RiverMend Health, Skyland Trail and Xhale; he reports income sources or equity of $10,000 or more from American Psychiatric Publishing, Bracket (Clintara), CME Outfitters, Takeda and Xhale; he has patents on a method and devices for transdermal delivery of lithium (US 6,375,990B1) and a method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by exvivo assay (US 7,148,027B2). Dr. Giampaolo Perna’s disclosures are as follows: Giampaolo Perna has received funding from Cariplo Foundation. He has served in the scientific advisor board of Medibio Ltd and has served as consultant for Lundbeck and Pfizer.
Publisher Copyright:
© Springer Nature Singapore Pte Ltd. 2020.
PY - 2020
Y1 - 2020
N2 - Anxiety disorders (ADs) are common psychiatric disorders, with a lifetime prevalence estimated at 33.7% in epidemiological studies. ADs are associated with serious disability and severe impairment in quality of life. Although several treatments [e.g. selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs), pregabalin, tricyclic antidepressants and benzodiazepines and/or cognitive-behaviour therapy (CBT)] are recommended, a large number of patients (i.e. from 30 to 70%) do not achieve complete remission. According to the novel paradigm of personalized medicine, the search of possible predictors of both disease vulnerability and treatment response might be the best way to prevent more accurately disease risk and to tailor the most effective treatment for each individual. Although a growing body of studies have proposed several endophenotypes/markers (i.e. neurochemical, neuroimaging, physiological, genetic and epigenetic endophenotypes/markers) as possible predictors of ADs susceptibility and/or treatment response, findings are not robust enough to be considered acceptable to incorporate in the clinical practice. In order to obtain more reliable results, larger studies with a multimodal approach, based on a combination of different biomarkers, are needed.
AB - Anxiety disorders (ADs) are common psychiatric disorders, with a lifetime prevalence estimated at 33.7% in epidemiological studies. ADs are associated with serious disability and severe impairment in quality of life. Although several treatments [e.g. selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs), pregabalin, tricyclic antidepressants and benzodiazepines and/or cognitive-behaviour therapy (CBT)] are recommended, a large number of patients (i.e. from 30 to 70%) do not achieve complete remission. According to the novel paradigm of personalized medicine, the search of possible predictors of both disease vulnerability and treatment response might be the best way to prevent more accurately disease risk and to tailor the most effective treatment for each individual. Although a growing body of studies have proposed several endophenotypes/markers (i.e. neurochemical, neuroimaging, physiological, genetic and epigenetic endophenotypes/markers) as possible predictors of ADs susceptibility and/or treatment response, findings are not robust enough to be considered acceptable to incorporate in the clinical practice. In order to obtain more reliable results, larger studies with a multimodal approach, based on a combination of different biomarkers, are needed.
KW - Anxiety disorders
KW - Biomarkers
KW - Disease susceptibility
KW - Endophenotypes
KW - Neuroimaging
KW - Personalized medicine
KW - Treatment outcome
UR - http://www.scopus.com/inward/record.url?scp=85078713285&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078713285&partnerID=8YFLogxK
U2 - 10.1007/978-981-32-9705-0_25
DO - 10.1007/978-981-32-9705-0_25
M3 - Chapter
C2 - 32002943
AN - SCOPUS:85078713285
T3 - Advances in Experimental Medicine and Biology
SP - 489
EP - 521
BT - Advances in Experimental Medicine and Biology
PB - Springer
ER -